Articles From: Emulex Appoints Industry Veteran Ali Hedayati as SVP and GM of the Network Visibility Products Division to Enbridge Inc. Acquires Interest in $650 Million Value Wind Portfolio From E.ON


Emulex Corporation (NYSE:ELX), a leader in network connectivity, monitoring and management, today announced the appointment of Ali Hedayati as senior vice president (SVP) and general manager (GM) of Network Visibility Products (NVP), responsible for overseeing global sales, services, marketing, engineering and strategic direction of the division.
Sign-up for Emulex Appoints Industry Veteran Ali Hedayati as SVP and GM of the Network Visibility Products Division investment picks
Emulex Corporation (NYSE:ELX), a leader in network connectivity, monitoring and management, today announced that it is delivering its OneConnect® (Skyhawk™) Ethernet technology for the new Quanta Cloud Technology (QCT) Open Compute Project (OCP) Networking (ON) 10Gb and 40Gb Ethernet (40GbE) Skyhawk Ethernet adapters.
Sign-up for Emulex Delivers High Performance Ethernet Technology for New QCT OCP Networking 10Gb and 40Gb Ethernet Adapters investment picks
Emulex Corporation (NYSE:ELX), a leader in network connectivity, monitoring and management, today announced that it has joined the 25Gb Ethernet (25GbE) Consortium to drive industry standardization.
Sign-up for Emulex Joins 25Gb Ethernet Consortium to Drive Industry Standardization investment picks
Emulex Corporation (NYSE:ELX), a leader in network connectivity, monitoring and management, announced a broad range of I/O connectivity solutions for the new HP ProLiant Gen9 rack and blade servers designed to support next generation workloads such as virtual desktop infrastructure (VDI), big data analytics, and emerging compute architectures such as network functions virtualization (NFV) for telco and OpenStack or OpenCompute-based cloud computing.
Sign-up for Emulex Optimizes and Scales Data Center Workloads with High Performance I/O for New HP ProLiant Gen9 Platforms investment picks
POWERING THE CLOUD – Emulex Corporation (NYSE:ELX), a leader in network connectivity, monitoring and management, announced the results of a study of 1,623 U.S. and European IT professionals, in which respondents provided insight into their enterprise data center networking environments.
Sign-up for Emulex Study Reveals Bandwidth and Network Speeds Exploding with Hyperscale Deployments investment picks
2014/11/3
Emulex Corporation: WHAT: About Emulex Emulex, a leader in network connectivity, monitoring and management, provides hardware and software solutions for global networks that support enterprise, cloud, government and telecommunications.
Sign-up for Emulex to Present at 2014 RBC Capital Markets’ Technology, Internet, Media & Telecommunications Conference investment picks
Emulex Corporation (NYSE:ELX): WHAT: About Emulex Emulex, a leader in network connectivity, monitoring and management, provides hardware and software solutions for global networks that support enterprise, cloud, government and telecommunications.
Sign-up for Emulex to Present at Barclays 2014 Global Technology Conference investment picks
2014/11/20
Emulex Corporation: WHAT: About Emulex Emulex, a leader in network connectivity, monitoring and management, provides hardware and software solutions for global networks that support enterprise, cloud, government and telecommunications.
Sign-up for Emulex to Present at Credit Suisse 2014 Annual Technology Conference investment picks
Enable Midstream Partners, LP (NYSE: ENBL) will announce third-quarter 2014 financial results before market hours on Tuesday, November 4, 2014, and will host a conference call to discuss the results that morning at 9 a.m. Eastern (8 a.m. Central). The dial-in number to access the conference call is 866.952.1908. The conference call ID is ENBLQ314.
Sign-up for Enable Midstream Announces Third-Quarter 2014 Financial Results Release Date and Conference Call Information investment picks
Enable Midstream Partners, LP (NYSE:ENBL) today announced that the board of directors of its general partner has declared a quarterly cash distribution of $0.3025 per unit on all outstanding common and subordinated units for the quarter ended Sept.
Sign-up for Enable Midstream Partners Increases Quarterly Distribution investment picks
DALLAS , Nov.
Sign-up for Enable Midstream Partners To Join The Alerian Natural Gas MLP Index investment picks
Enable Midstream Partners, LP (NYSE: ENBL) (the "Partnership”) today announced financial results for third quarter 2014.
Sign-up for Enable Midstream Reports Third Quarter 2014 Financial Results investment picks
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs primarily in the infectious disease field, today announced that the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted positive opinions for AbbVie’s investigational, all-oral, interferon-free treatment of VIEKIRAX™ (a combination of ombitasvir, paritaprevir (ABT-450) and ritonavir) plus EXVIERA™ (dasabuvir), with or without ribavirin (RBV), for patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, and VIEKIRAX™ only, with RBV, for patients with genotype 4 (GT4) HCV infection.
Sign-up for Enanta Announces CHMP Grants Positive Opinions of AbbVie’s VIEKIRAX™ (ombitasvir/paritaprevir(ABT-450)/ritonavir) + EXVIERA™ (dasabuvir) for the Treatment of Chronic Hepatitis C in Europe investment picks
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced detailed results from AbbVie’s open-label, Phase 2b PEARL-I study in patients with genotype 4 (GT4) chronic hepatitis C virus (HCV). PEARL-I studied AbbVie’s all-oral, interferon-free investigational treatment combining two direct-acting antivirals (ABT-450/ritonavir and ombitasvir) with or without ribavirin (RBV) for 12 weeks in non-cirrhotic adult patients with chronic genotype 1b (GT1b) and GT4 hepatitis C virus (HCV) infection.
Sign-up for Enanta Announces Results from Phase 2b PEARL-I Study in Genotype 4 Chronic Hepatitis C Patients at The Liver Meeting 2014® investment picks
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced at The Liver Meeting ® 2014 results from studies in chronic hepatitis C virus (HCV) patients with human immunodeficiency virus type 1 (HIV-1) co-infection (TURQUOISE-I) and liver transplant recipients (CORAL-I). New, detailed results from part one of the Phase 2 portion of AbbVie’s Phase 2/3 open-label study, TURQUOISE-I, showed that patients co-infected with genotype 1 (GT1) HCV and HIV-1 receiving AbbVie’s investigational treatment and ribavirin (RBV) for 12 weeks or 24 weeks achieved a sustained virologic response rate 12 weeks post-treatment (SVR 12 ) of 93.5 percent (n=29/31) and 90.6 percent (n=29/32), respectively.
Sign-up for Enanta Announces Results from TURQUOISE-I Study in Chronic Hepatitis C Patients with HIV-1 Co-infection and from the CORAL-I Study In Liver Transplant Recipients at The Liver Meeting 2014® investment picks
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that 25 abstracts reporting the results of hepatitis C virus (HCV) treatment regimens containing ABT-450, Enanta’s lead protease inhibitor, or ABT-493, Enanta’s next-generation protease inhibitor, have been accepted for presentation at The Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), being held November 7-11, 2014 in Boston, MA.
Sign-up for Enanta Pharmaceuticals Announces Data Presentations on Regimens Containing ABT-450 or ABT-493 to be Presented at the American Association for the Study of Liver Diseases (AASLD) investment picks
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that it has decided not to exercise its co-development option for ABT-493, Enanta’s next-generation protease inhibitor for hepatitis C virus (HCV) being developed in Enanta’s collaboration with AbbVie.
Sign-up for Enanta Pharmaceuticals Provides Update on its Collaboration Agreement with AbbVie investment picks
Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today reported financial results for its fiscal fourth quarter and year ended September 30, 2014.
Sign-up for Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2014 investment picks
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that it plans to report its fiscal fourth quarter and year ended September 30, 2014 financial results before the U.S. markets open on November 24, 2014.
Sign-up for Enanta Pharmaceuticals to Host Conference Call to Discuss Financial Results for the Fiscal Fourth Quarter and Year Ended September 30, 2014 investment picks
Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that Jay R.
Sign-up for Enanta Pharmaceuticals to Present at Credit Suisse 2014 Healthcare Conference investment picks
Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs primarily in the infectious disease field, today announced that Jay R.
Sign-up for Enanta Pharmaceuticals to Present at the Deutsche Bank 2014 BioFEST investment picks
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that the company has entered into an agreement to regain full rights from Novartis to EDP-239, an NS5A inhibitor currently in phase 1 development for hepatitis C virus (HCV). “Novartis notified Enanta that as part of an ongoing portfolio transformation, HCV research would no longer be a strategic focus for Novartis,” stated Jay R.
Sign-up for Enanta Regains Full Rights to NS5A Inhibitor EDP-239 for Hepatitis C Virus from Novartis investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0982483001&sourceType=1 http://media3.marketwire.com/logos/20140922-922enb-logo.jpg CALGARY, ALBERTA --
Sign-up for Enbridge Announces 33% Dividend Increase, Financial Restructuring Plans, Revised Payout Policy and 2015 Adjusted Earnings Guidance investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0982823001&sourceType=1 http://media3.marketwire.com/logos/20140922-922enb-logo.jpg CALGARY, ALBERTA --
Sign-up for Enbridge Announces Adoption of Advance Notice Bylaw investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0969814001&sourceType=1 http://media3.marketwire.com/logos/20140922-922enb-logo.jpg CALGARY, ALBERTA --
Sign-up for Enbridge Day 2014 Investment Community Conference to be Webcast investment picks
http://media.marketwire.com/attachments/201411/81245_enbridge.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1156614&ProfileId=051205&sourceType=1 HOUSTON, TX --
Sign-up for Enbridge Energy Management, L.L.C. Confirms Amount of Share Distribution for Third Quarter 2014 investment picks
http://media.marketwire.com/attachments/201410/282913_ENB_LOGO_CMYK_C.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1155511&ProfileId=051205&sourceType=1 HOUSTON, TX --
Sign-up for Enbridge Energy Partners, L.P. Declares Distribution and Reports Earnings for Third Quarter 2014 investment picks
http://media.marketwire.com/attachments/201410/282913_ENB_LOGO_CMYK_C.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1163397&ProfileId=051205&sourceType=1 HOUSTON, TX --
Sign-up for Enbridge Energy Partners, L.P. to Present at the 2014 Wells Fargo Securities Energy Symposium investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0981404001&sourceType=1 http://media3.marketwire.com/logos/20140922-922enb-logo.jpg CALGARY, ALBERTA --
Sign-up for Enbridge Inc. Acquires Interest in $650 Million Value Wind Portfolio From E.ON investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Emulex Appoints Industry Veteran Ali Hedayati as SVP and GM of the Network Visibility Products Division to Enbridge Inc. Acquires Interest in $650 Million Value Wind Portfolio From E.ON
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent